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Abstract: Daunorubicin is an anticancer drug, and cholesterol is involved in cancer progression, but
their relationship has not been defined. In this study, we developed a novel experimental model that
utilizes daunorubicin, cholesterol, and daunorubicin plus cholesterol in the same cells (H35) to search
for the role of nuclear lipid microdomains, rich in cholesterol and sphingomyelin, in drug resistance.
We find that the daunorubicin induces perturbation of nuclear lipid microdomains, localized in the
inner nuclear membrane, where active chromatin is anchored. As changes of sphingomyelin species in
nuclear lipid microdomains depend on neutral sphingomyelinase activity, we extended our studies
to investigate whether the enzyme is modulated by daunorubicin. Indeed the drug stimulated the
sphingomyelinase activity that induced reduction of saturated long chain fatty acid sphingomyelin
species in nuclear lipid microdomains. Incubation of untreated-drug cells with high levels of
cholesterol resulted in the inhibition of sphingomyelinase activity with increased saturated fatty acid
sphingomyelin species. In daunodubicin-treated cells, incubation with cholesterol reversed the action
of the drug by acting via neutral sphingomyelinase. In conclusion, we suggest that cholesterol and
sphingomyelin-forming nuclear lipid microdomains are involved in the drug resistance.
Keywords: sphingomyelin; cholesterol; nuclear membrane; nuclear lipid microdomains; daunorubicin
1. Introduction
Drug resistance is the biggest obstacle for cancer treatment. Large-scale cancer drug studies
provide information about the role of daunorubicin (DNR) to delay cell growth. DNR inhibits DNA
synthesis, demonstrated by radiolabelled thymidine incorporation, in H35 hepatoma cells [1] and
SUP-T1 lymphoma T-lymphoblast cells [2]. In HL-60 cells, DNR reduces cell viability and promotes
apoptosis by modifying NF-κB; this effect is facilitated by Flavokawain B [3]. DNR-induced apoptosis
of acute lymphoblastic leukemia cells is increased by the loss of the signal transducer and activator of
transcription 6 (STAT6) [4]. Recently, liposomal cytarabine-daunorubicin CPX-351 has been approved
as a new drug for treating acute myeloid leukemia [5]. The use of DNR combined with cytarabine
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and trans retinoic acid was able to induce complete remission of concomitant myelodysplasia-related
acute myeloid leukemia and acute promyelocytic leukemia in a 43-year old patient [6]. A promising
cancer therapy has been developed endocapsuling DNR in injectable polymeric nanocontainers [7].
The focus on DNR resistance has expanded from its origin in drug regulation to multiple biological
processes of cancer [8,9]. Discovering cancer-resistance drivers and metabolites involved in the process
is an interesting research area. In Breast Cancer MCF-7 Cells, P-Glycoprotein is recognized to be
implicated in DNR resistance [10]. High expression of the ATP-binding cassette-multi-drug efflux
protein 1 confers resistance to DNR in mucosal-associated invariant T cells [11]. In addition, altered
expression of atg5, HSPA1B, collagen XIII, collagen XXAI, slug, snail, and zeb1 genes has been related
to multiple drug resistance, including DNR-resistance [12]. In a previous study we found a critical role
of cholesterol (CHO) and sphingomyelin (SM) in DNR resistance [2].
In particular, treatment with CHO reverses the effects of DNR in lymphoma lymphoblastic cells,
by reducing neutral sphingomyelinase (nSMase) activity, increased with the drug [2]. At present,
studies on the mechanisms underlying the relation between structure and function of nSMase show
that the activation of the enzyme is influenced by pH, ions as Ca2+, Mg2+, and Mn+, phosphorylation,
and anionic phospholipid-signaling molecule interaction [13]. Implication of SM metabolism in
DNR-induced apoptosis has been widely described [14,15]. A majority of the current studies
concentrate on finding sphingolipids that are changed in whole cancer cells with DNR, without
information regarding nuclear lipids that might perturb chromatin processes. Our results on the role
of nuclear lipids support the notion that SM and CHO are organized in the inner nuclear membrane
to form nuclear lipid microdomains (NLM) that act as platform for active chromatin attachment [7],
DNA duplication [8] and transcription [7], vitamin D-vitamin D receptor link [9], dexamethasone
action on cell proliferation [10]. Considerable evidence has implicated CHO in the change of NLM in
cancer cells [11]. Numerous studies have shown that the interaction CHO-SM to form microdomains
or lipid rafts depends on the length of the acyl chain of SM [16,17]. Notably, our own recent study
found that in NLM from hepatoma cells (H35), the fatty acids (FAs) of SM shifts from very long FAs
(24:0 SM) to long FAs (16:0 SM) in comparison with normal cells, in association with an increase of
proteins involved in hepatocarcinogenesis [18].
In this study, we developed a novel experimental model, which utilizes DNR, CHO, and DNR +
CHO in the same cells (H35) to search for the role of NLM in drug resistance. Applying our study to
hepatoma cells, we defined the perturbation of NLM induced by DNR treatment and investigated SM
metabolism as a candidate pathway involved in the CHO-induced drug resistance.
2. Results
2.1. Specific Neutral Sphingomyelinase Down-Regulation with Daunorubicin Treatment
Considerable research has implicated DNR as an anti-cancer drug [1,3–7]. Previously, we reported
that DNR delayed lymphoma cell growth and high levels of CHO induced DNR-resistance [2]. Here, we
explored the underlying mechanisms of this effect considering the important relationship of CHO
and SM in the nucleus, regulated by nSMase [19]. A dose-response of DNR study revealed that, by
increasing the dose from 0.2 to 2 µM, the number of cells was sharply reduced for concentrations
higher than 1 µM (Figure 1, Supplementary Table S1) and therefore this concentration was used
for all experiments; 800 nM CHO was chosen because it corresponds to a blood condition of
hypercholesterolemia [2]. Under these conditions (1 µM DNR and/or 800 nM CHO), we first set
out to investigate the effect of DNR and/or CHO on aSMase and nSMase gene expression in order
to exclude the involvement of aSMase. We found the down-regulation of nSMase gene expression
with DNR. As can be seen, CHO alone did not change nSMase and, when combined with DNR, did
not allow the DNR to act (Figure 2, Supplementary Table S1). Results showed that aSMase was not
changed with all treatments (Figure 2, Supplementary Table S1).
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Figure 1. Dose-dependent effect of DNR on H35 cells: 300 × 103 cells were seeded and cultured with 
increasing doses of DNR from 0.2 to 2.0 μM. CTR, control cells. Data indicate cell number after 24 h 
of culture and are expressed as the mean ± SD of three independent experiments. ∗ p < 0.05 versus 
CTR. 
 
Figure 2. Effect of DNR, CHO, DNR–CHO on aSMase and nSMase gene expression. Cells were treated 
with 1 μM DNR or 800 nM CHO or 1 μM DNR + 800 nM CHO. RTqPCR analysis was performed on 
control (CTR) and treated cells, by using GAPDH as a housekeeping gene. On the ordinate, mRNA 
relative expression = mRNA of treated cells/mRNA of control cells. Data are expressed as the mean ± 
SD of three independent experiments performed in three PCR replicates. ∗ p < 0.05. 
2.2. Sphingomyelin Metabolism of Nuclear Lipid Microdomains as an Emerging Target of Daunorubicin in 
Cancer: Role of Cholesterol in Drug-Resistance 
To clarify the role of NLM rich in CHO and SM in our experimental system, hepatoma cells were 
treated with DNR, CHO or DNR + CHO and NLM were purified and analyzed. First, we studied the 
protein expression of markers for NLM purity, such as STAT3 and lamin B, and endoplasmic 
membrane marker, such as giantin, in order to exclude possible contamination during extraction, as 
previously reported [16]. For comparison, the proteins were analysed in nuclei-free lysates (NFL), 
prepared from the control sample, in which the presence of STAT3 and giantin and the absence of 
lamin B were shown. We found both the presence of STAT3, lamin B and the absence of giantin in all 
samples, indicating a high level of purification of NLM (Figure 3a). Only DNR treatment induced a 
significant reduction of STAT3 and lamin B protein (Figure 3b, Supplementary Table S1). Then, we 
focused the attention on the involvement of SM metabolism in NLM as a target of DNR and on CHO-
induced drug resistance. Thus, we performed analysis of the nSMase protein content in NLM. Results 
showed that nSMase expression was significantly repressed only with DNR treatment (Figure 4a,b, 
Figure 1. Dose-dependent effect of DNR on H35 cells: 300 × 103 cells were seeded and cultured with
increasing doses of DNR from 0.2 to 2.0 µM. CTR, control cells. Data indicate cell number after 24 h of
culture and are expressed as the mean ± SD of three independent experiments. ∗ p < 0.05 versus CTR.
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Figure 2. Effect of DNR, CHO, DNR–CHO on aSMase and nSMase gene expression. Cells were treated
with 1 µM DNR or 800 nM CHO or 1 µM DNR + 800 nM CHO. RTqPCR analysis was performed on
control (CTR) and treated cells, by using GAPDH as a housekeeping gene. On the ordinate, mRNA
relative expression = mRNA of treated cells/mRNA of control cells. Data are expressed as the mean ±
SD of three independent experiments performed in three PCR replicates. ∗ p < 0.05.
. . i li t li f l i i i i i arget of aunorubicin in
Cancer: Role of Cholesterol in Drug-Resistance
To clarify the role of NLM rich in CHO and SM in our experimental system, hepatoma cells were
treated with DNR, CHO or DNR + CHO and NLM were purified and analyzed. First, we studied
the protein expression of markers for NLM purity, such as STAT3 and lamin B, and ndoplasmic
membrane marker, such s giantin, in order to exclude possible contamination duri g xtraction, as
previously reported [16]. For comparison, the proteins were analysed in nuclei-free lysates (NFL),
r pared from the control sample, in which the presence of STAT3 nd gianti and the absenc of lamin
B were shown. W found both the presence of STAT3, lamin B and the bsence of gi tin in ll samples,
indicating a high level of purification of NLM (Figure 3a). Only DNR treatment induced a sig ificant
reduction of STAT3 nd lamin B protein (Figure 3b, Supplementary Table S1). Th n, we focused the
attention on the involvement of SM metabolism in NLM as a target of DNR and on CHO-induced drug
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resistance. Thus, we performed analysis of the nSMase protein content in NLM. Results showed that
nSMase expression was significantly repressed only with DNR treatment (Figure 4a,b, Supplementary
Table S1). Consistent with the results, we assayed the enzyme activity in NLM purified from H35 cells
after different treatments. Strikingly, upon DNR treatment, the nSMase activity increased strongly, and
CHO or DNR–CHO treatment slightly inhibited the activity in comparison with the control sample
(Figure 4c, Supplementary Table S1). Since nSMase activity modified the SM content, there was the
possibility that the composition of SM species was changed in the different experimental samples.
To consolidate this hypothesis, we performed UFLC-MS/MS analysis for SM species in NLM from
control and treated samples, by using 16:0 SM, 18:1 SM, and 24:0 SM external calibrators. Notably, DNR
reduced mainly 16:0 SM; differently, CHO and DNR + CHO increased only saturated FA SM (Figure 5a,
Supplementary Table S1). In addition, to have a deeper insight into SM species, we analyzed the
areas of all the peaks identified on the basis of their molecular weights. Considering the high level of
SM 16:0, DNR treatment induced mainly a loss of saturated chain SM species; CHO and DNR–CHO
treatment increased only long-chain saturated FAs (Figure 5b, Supplementary Table S1).
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Figure 3. Immunobl tting a alysis of nSMase, STAT3, lamin b, and giantin in nuclear lipid microdomains.
For omparison, on the left, are the proteins pr sent in nuclei fr e-lysates (NFL) prepared from
control sample. Cells were treated with 1 µM DNR or 800 nM CHO or 1 µM DNR + 800 nM
CHO. (a) The position of the 92 kDa for STAT3, 68 kDa for lamin b and 367 kDa for giantin was
evaluated in relation to the position of molecular size standards; (b) the area density was quantified
by densitometry scanning and analysis with Scion Image. Data represent the mean ± SD of six
independent experiments. * p < 0.05.
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3. Discussion
Daunorubicin is an anticancer drug that belongs to the anthracyclines class, a well-known inducer
of DNA damage through generation of reactive oxygen species [20,21]. However, the intranuclear
site where the damage is induced has not been investigated. Consolidating our previous studies that
hint at a role of NLM in anchoring active chromatin and in regulating duplication and transcription
processes [16–19,22,23], we demonstrate that DNR induces perturbation of NLM. We found a reduction
of NLM markers, such as STAT3 and lamin B, usually used as reference proteins [16–19,22,23].
Excluding a possible experimental error because the experiments were repeated many times, we
suppose that the DNR induces damage of the NLM organization. Consequently, part of the marker
proteins are lost during the extraction. Interestingly, despite that DNR reduces the nSMase protein
content, it strongly stimulates the nSMase enzyme activity that is responsible for the reduction of SM
species particularly with saturated long-chain FAs. It is difficult to explain why the nSMase protein
is reduced. There are two possibilities: (1) the demonstrated down-regulation of the nSMase gene
expression is responsible for the reduction of the enzyme in different cellular sites and, therefore, also
in NLM; (2) the protein is lost together with STAT3 and lamin B. Furthermore, it is possible to suggest
another mechanism of action of the DNR. This study adds to an emerging literature implicating
the role of anthracyclines in cancer via SM metabolism [24]. Our results show that the DNR, by
activating nSMase, reduces mainly saturated long-chain FA SM species. In H35 cells, NLMs are
rich in SM species with saturated long chains [18]. It is known that CHO prefers saturated SM to
establish more favorable entropic interactions essential for the formation of NLM [25]. Therefore, it
cannot be ruled out that DNR, by reducing the SM species, destructures NLM with loss of STAT3 and
lamin B. These different hypotheses open up two scenarios: (1) the DNR first destroys NLM and then
activates nSMase or (2) the DNR acts directly on nSMase activity and consequently destroys the NLMs.
The latter mechanism would explain why CHO, by reducing nSMase activity and enriching the NLM
of saturated long-chain FA SM, has an opposite action to that of DNR, if added alone. If the CHO is
added together with the DNR, it does not allow the drug to act. It is important to consider that the dose
used for the experiments corresponds to a condition of hypercholesterolemia [2]. We demonstrated
that cancer cells incorporate CHO by inducing severe hypocholesterolemia. CHO entering the cancer
cells stimulates their proliferation [2]. A systematic review on statins and colon cancer highlights that
lowering blood cholesterol level reduces colorectal carcinogenesis [26]. The role of CHO in cancer
is widely demonstrated even if the studies on mechanism of action are still subject to discussion.
As more studies begin to elucidate the role of CHO inside the cancer cells, we propose to consider that
hypercholesterolemia might induce drug resistance by changing the lipids inside the nucleus, in NLM.
The study suggests that hypercholesterolemia can be harmful in a patient with cancer as responsible
for drug-resistance.
4. Materials and Methods
4.1. Materials
H35 hepatoma cells were obtained from the European Collection of Animal Cell Cultures (Salisbury,
UK). DMEM, bovine serum albumin (BSA), dithiothreitol (DTT), fetal bovine serum (FBS), methanol,
3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide, 2-propanol, metyl-tert-butyl ether,
formic acid, chloroform, DNR and CHO were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Lipid standards 16:0 SM, 18:1 SM, 24:0 SM were purchased from Avanti (Avanti Polar, Alabaster,
AL, USA). Anti-giantin, anti-signal transducer and activator of transcription 3 (STAT3), anti-nSMase,
and anti-aSMase antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA);
anti-lamin B was obtained from Oncogene (Boston, MA, USA).
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4.2. Cell Culture
H35 hepatoma cells were grown as previously reported [18]. For dose-dependent effect of DNR
study, cells were seeded at 10 × 104/mL concentration, incubated with increasing doses of DNR
from 0.2 to 2.0 µM and counted after 24 h. For all experiments, four lots of the cells at 10 × 106
concentration were prepared: the control sample (C) without DNR and CHO, the experimental sample
with 800 nM CHO [11] or with 1 µM DNR [2] or with 800 nM CHO + 1 µM DNR. After 24 h of culture,
a small amount of the cells was used for aSMase and nSMase gene expression and the remaining part
NLM purification.
4.3. Nuclei-Free Lysates
The cells were washed twice with phosphate-buffered saline (PBS) and centrifuged at 800× g for
10 min. The resulting pellet was suspended in hypotonic buffer (1.5 M sucrose, 3 mM CaCl2, 2 mM
magnesium acetate, 0.5 mM DTT, 1 mM phenylmethylsulfonylfluoride (PMSF), 3 mM Tris-HCl, pH 8.0
(1 mL/106 cells)), gently homogenized using a tight-fitting Teflon-glass homogenizer and centrifuged
at 500× g for 30 min at 4 ◦C for nuclei-free lysates (NFL) preparation, as previously reported [27]
4.4. Purification of Nuclear Lipid Microdomains
NLMs were purified H35 cell nuclei as previously reported [10]. Briefly, the homogenized
cells were treated with 1% Triton X-100 in hypotonic buffer (1.5 M sucrose, 3 mM CaCl2, 2 mM
magnesium acetate, 0.5 mM DTT, 1 mM PMSF, 3 mM Tris-HCl, pH 8.0) 0.5:1 vol/vol and then treated
with 1 M sucrose, followed by centrifugation to isolate whole nuclei. The removal of the external
nuclear membranes with preservation of the inner nuclear membranes, was obtained by a 10 mM
Tris solution containing 2.5 mM MgCl2, 0.5 mM PMSF, and 1% Triton X-100. NLMs were extracted
from inner nuclear membrane with a cushion of 80% sucrose with a gradient of 15–40% sucrose on
top. After overnight centrifugation, the gradient had five 2-mL fractions plus two 1-mL floating
fractions. The latter fractions were carefully collected, diluted five times with 25 mM HEPES-HCl
solution containing 150 mM NaCl, and centrifuged at 100,000× g for 2 h to obtain a pellet of NLM.
4.5. Reverse Transcription Quantitative PCR (RT-qPCR)
After 24 h of culture, cells were used for total RNA extraction by using RNAqueous®-4PCR kit
and for RT-qPCR performed by using Master Mix TaqMan®Gene Expression with a 7.500 RT-PCR
instrument (Applied Biosystems, Monza, Italy), as previously reported [17]. The targeted genes
were: SM phosphodiesterase 1 (SMPD1, Hs03679347_g1) and SM phosphodiesterase 4 (SMPD4,
Hs04187047_g1). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Hs99999905_m1) was used
as a housekeeping gene. Relative quantification of SMPD1 and SMPD4 genes, after 24 h of drug
treatment, was calculated in comparison to the relative controls and normalized to the housekeeping
gene GAPDH, using the 2−∆∆Ct method.
4.6. Protein Content
Total protein concentration was determined spectrophotometrically at 750 nm by using bovine
BSA as a standard, as previously reported [16].
4.7. Electrophoresis and Western Blot Analysis
Proteins (∼30 µg) underwent SDS-PAGE electrophoresis in 12% polyacrylamide slab gel for
nSMase, STAT3, lamin B and 8% for giantin, according as previously reported [16]. The transfer
of protein was carried out into nitrocellulose in 90 min, the membranes were blocked for 30 min
with 5% nonfat dry milk in PBS (pH 7.5), and incubated overnight at 4 ◦C with primary antibodies.
The blots were treated with horseradish-conjugated secondary antibodies for 90 min. Visualization
was performed with the Enhanced Chemiluminescence (ECL) kit from Amersham (GE Healthcare
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Europe GmbH, Milano, Italy). The position of the protein was indicated in relation to the position of
molecular size standards. The area density was evaluated by densitometry scanning and analysis with
Scion Image software (https://scion-image.software.informer.com/4.0/).
4.8. nSMase Activity Assay
H35 cells were suspended in 0.1% NP-40 detergent in PBS, sonicated for 30 s on ice at 20 watt,
kept on ice for 30 min and centrifuged at 16,000× g for 10 min. The supernatants were used for nSMase
assay. The enzyme activity was assayed with Amplex Red Sphingomyelinase assay kit (Invitrogen,
Monza, Italy) by using 60 µg proteins/10 µL Tris-MgCl2 pH 7.4. The fluorescence was measured with
FLUOstar Optima fluorimeter (BMG Labtech, Monza, Italy), by using the filter set of 360 nm excitation,
and 460 nm emission.
4.9. Lipid Extraction and UFLC MS/MS Analysis
Lipid extraction and UFLC MS/MS analysis were performed as reported by Lazzarini et al.
(2015) [18] The 16:0 SM, 18:1 SM, 24:0 SM standards were prepared and dissolved in
chloroform/methanol (9:1 vol/vol) at 10 µg/mL final concentration. The stock solutions were stored
at −20 ◦C. Working calibrators were prepared by diluting stock solutions with methanol to 500:0, 250:0,
100:0, and 50:0 ng/mL final concentrations. Twenty microliters of standards or lipids extracted from
serum was injected after purification with specific nylon filters (0.2 µm). Analyses were carried out by
using the Ultra Performance Liquid Chromatography system tandem mass spectrometer (Applied
Biosystems, Italy). The samples were separated on a Phenomenex Kinetex phenyl-hexyl 100 A column
(50 × 4.60-mm diameter, 2.6-µm particle diameter) with a precolumn security guard Phenomenex
ULTRA phenyl-hexyl 4.6. For SM, column temperature was set at 50 ◦C and flow rate to 0.9 mL/min.
Solvent A was 1% formic acid; solvent B was 100% isopropanol containing 0.1% formic acid. The run
was performed for 3 min in 50% solvent B and then along a gradient to reach 100% solvent B in
5 min. The system needed to be reconditioned for 5 min with 50% solvent B before the next injection.
The SM species were identified by using positive turbo-ion spray and modality multipole-reaction
monitoring [18].
4.10. Statistical Analysis
Data were expressed as means ± SD and their significance was checked by Student’s t-test.
* p < 0.05 versus control samples (CTR).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/11/
3424/s1.
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